$267.14
Value $644B
JNJ and NVO stock compared: price, dividend, valuation and results, from SEC filings.
$267.14
Value $644B
$38.87
Value $173B
Johnson & Johnson (JNJ) has a market value of $644B and Novo Nordisk A/S (NVO) $173B. Over the last year, with dividends, JNJ moved +36.6% and NVO -14.2%. The P/E is 40.0 for JNJ and 10.7 for NVO. Dividend yield: JNJ 1.98%, NVO 4.73%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
JNJ$644B
NVO$173B
JNJ is 3.7 times NVO
Revenue, 12 months
JNJ$99.3B
NVO$48.6B
JNJ is 2.0 times NVO
Net income, 12 months
JNJ$16.1B
NVO$16.1B
About the same
Operating margin
JNJ–
NVO41.3%
ROIC
JNJ12.4%
NVO31.0%
18.6 points apart
P/E
JNJ40.0
NVO10.7
JNJ is 3.7 times NVO
Dividend yield
JNJ2.0%
NVO4.7%
2.7 points apart
5-year return
JNJ+89.1%
NVO-24.3%
113.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
JNJ+89.1%
NVO-24.3%
| Period | JNJWith dividends | NVOWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +36.6%Price +33.6% | -14.2%Price -18.3% |
| 3 years since November 17, 2023 | +94.2%+24.8% a yearPrice +78.3% | -58.2%-25.2% a yearPrice -61.7% |
| 5 years since November 18, 2021 | +89.1%+13.6% a yearPrice +64.5% | -24.3%-5.4% a yearPrice -32.4% |
| 10 years since November 21, 2016 | +202.7%+11.7% a yearPrice +132.3% | +204.0%+11.8% a yearPrice +141.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
JNJJohnson & JohnsonNVONovo Nordisk A/S
| Price | $267.14 | $38.87 |
|---|---|---|
| Market value | $644B | $173B |
| Enterprise value (EV) | $671B | $191B |
| P/E | 40.0 | 10.7 |
| P/E, 5-year median | 21.9 | 35.5 |
| P/B | 7.9 | 5.7 |
| EV/EBIT | 37.8 | 9.5 |
| Free cash flow yield | 3.2% | 5.4% |
| Revenue, 12 months | $99.3B | $48.6B |
|---|---|---|
| Net income, 12 months | $16.1B | $16.1B |
| Free cash flow, 12 months | $20.6B | $9.3B |
| Earnings per share, 12 months | $6.59 | $3.62 |
| Revenue growth, year on year | 6.1% | 6.4% |
| Revenue growth a year, past | +2.7%over 5 years | +19.5%over 5 years |
| EPS growth a year, past | +14.9%over 5 years | +20.7%over 5 years |
| Gross margin | 67.6% | 81.0% |
|---|---|---|
| Operating margin | – | 41.3% |
| Net margin | 16.2% | 33.1% |
| ROIC | 12.4% | 31.0% |
| ROE | 19.7% | 52.8% |
| Cash | $17.2B | $4.2B |
|---|---|---|
| Total debt | $44.7B | $21.9B |
| Net debt / EBITDA | 1.1 | 0.8 |
| Interest cover | 18.0× | – |
| Dividend yield | 2.0% | 4.7% |
|---|---|---|
| Dividend per share, 12 months | $5.28 | $1.84 |
| Dividend growth a year, past | +5.3%over 5 years | +19.7%over 5 years |
| Buyback yield | 0.9% | 0.1% |
| Shareholder yield | 2.9% | 4.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($644B) is about 3.7 times Novo Nordisk A/S ($173B), at today's prices.
Since November 21, 2016, JNJ's price moved +132.3% and NVO's +141.0%. With dividends: JNJ +202.7% (+11.7% a year), NVO +204.0% (+11.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.98% for Johnson & Johnson and 4.73% for Novo Nordisk A/S. Over the last twelve months they paid $5.28 and $1.84 per share.
At today's price, the P/E is 40.0 for JNJ and 10.7 for NVO. The median of the last five years was 21.9 and 35.5, which shows where each stands against its own past.
Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 33.1% for Novo Nordisk A/S, and the operating margin – and 41.3%. Revenue was $99.3B and $48.6B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.